Market Overview
The Europe subcutaneous immunoglobulin (SCIG) sector is witnessing remarkable growth driven by rising prevalence of primary immunodeficiency diseases (PIDs), increasing patient preference for home-based therapies, and continuous advancements in biologics. Valued at USD 2.5 billion in 2024, the sector is projected to grow at a CAGR of 9.0% from 2025 to 2034,...
English
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)